Publication Name	World Journal of Diabetes
Manuscript ID	61327
Country	Brazil

Received	2020-12-02 14:27
Peer-Review Started	2020-12-02 14:29
To Make the First Decision
Return for Revision	2020-12-24 19:42
Revised	2020-12-29 15:14
Second Decision	2021-02-22 03:35
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-03-08 06:34
Articles in Press	2021-03-08 06:34
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-05-17 06:15
Typeset the Manuscript	2021-06-03 00:26
Publish the Manuscript Online	2021-06-04 13:47

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Minireviews
Article Title	Diabetes and inflammatory diseases: An overview from the perspective of Ca2+/3'-5'-cyclic adenosine monophosphate signalling
Manuscript Source	Invited Manuscript
All Author List	Leandro Bueno Bergantin
Funding Agency and Grant Number
Corresponding Author	Leandro Bueno Bergantin, PhD, Professor, Department of Pharmacology, Universidade Federal de São Paulo, Rua Pedro de Toledo, 669–Vila Clementino, São Paulo 04039-032, Brazil. leanbio39@yahoo.com.br
Key Words	Diabetes, cancer, hypertension, dementia; Ca2+/3'-5'-cyclic adenosine monophosphate signalling; Ca2+ channel blockers; Pharmacotherapy; Neurodegeneration; COVID-19
Core Tip	There are several reviews in the literature about diabetes and inflammatory diseases. Nonetheless, to my knowledge, this is the first review which clearly discussed the role of Ca2+/3'-5'-cyclic adenosine monophosphate (cAMP) signalling in the link among diabetes and inflammatory diseases. This article also included a timeline of the major events in Ca2+/cAMP signalling field, and also discussed recent reports about the role of Ca2+ channel blockers for preventing Ca2+ signalling disruption due to coronavirus disease 2019 (COVID-19), including the correlation between COVID-19 and diabetes.
Publish Date	2021-06-04 13:47
Citation	Bergantin LB. Diabetes and inflammatory diseases: An overview from the perspective of Ca2+/3'-5'-cyclic adenosine monophosphate signalling. World J Diabetes 2021; 12(6): 767-779
URL	https://www.wjgnet.com/1948-9358/full/v12/i6/767.htm
DOI	https://dx.doi.org/10.4239/wjd.v12.i6.767

Full Article (PDF)	WJD-12-767.pdf
Full Article (Word)	WJD-12-767.docx
Manuscript File	#61327_Auto_Edited_LM-Webster J-Clear.docx
Answering Reviewers	61327-Answering reviewers.pdf
Audio Core Tip	61327-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	61327-Conflict-of-interest statement.pdf
Copyright License Agreement	61327-Copyright license agreement.pdf
Peer-review Report	61327-Peer-review(s).pdf
Scientific Misconduct Check	61327-Bing-Wang JL-1.jpg
Scientific Misconduct Check	61327-Bing-Fan JR-2.png
Scientific Misconduct Check	61327-Scientific misconduct check.pdf
Scientific Editor Work List	61327-Scientific editor work list.pdf